AstraZeneca has trailed rivals such as Novartis and Pfizer in its willingness to purchase promising drugs that were discovered outside their own laboratories, and the drugmaker now is playing catch-up. Over the past few months AstraZeneca has signed several deals totaling up to $1.6 billion to license drug candidates and may be considering additional alliances.

Related Summaries